TDMS Study 96007-03 Pathology Tables
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
FINAL # 3 RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: 1746-01-6
Lock Date: 06/28/01
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 98 98 98 98 98 98
Early Deaths
Moribund Sacrifice 19 27 15 19 17 17
Natural Death 9 6 10 15 14 15
Dosing Accident 5
Survivors
Terminal Sacrifice 25 21 23 19 22 21
Animals Examined Microscopically 53 54 53 53 53 53
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (52) (54) (53) (52) (53) (53)
Carcinoma 1 (2%)
Intestine Small, Jejunum (51) (54) (53) (53) (53) (52)
Leiomyoma 1 (2%)
Liver (53) (54) (53) (53) (53) (53)
Carcinoma, Metastatic, Pancreas 2 (4%)
Carcinoma, Metastatic, Uterus 2 (4%)
Cholangiocarcinoma 1 (2%) 3 (6%) 8 (15%)
Cholangiocarcinoma, Multiple 1 (2%) 17 (32%)
Hepatocellular Adenoma 1 (2%) 10 (19%)
Hepatocellular Adenoma, Multiple 3 (6%)
Hepatocholangioma 2 (4%)
Mesentery (2) (2) (1) (6) (8)
Carcinoma, Metastatic, Uterus 1 (17%)
Schwannoma Malignant 1 (50%)
Oral Mucosa (2) (9) (16) (16) (22) (29)
Gingival, Squamous Cell Carcinoma 1 (50%) 2 (22%) 1 (6%) 4 (18%) 10 (34%)
Pancreas (51) (54) (52) (53) (52) (51)
Carcinoma, Metastatic, Uterus 1 (2%)
Acinus, Adenoma 1 (2%)
Acinus, Carcinoma 2 (4%)
Stomach, Forestomach (53) (54) (53) (53) (53) (53)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (53) (54) (53) (53) (53) (53)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (53) (54) (53) (52) (53) (52)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (54) (53) (53) (53) (53)
Adenoma 1 (2%) 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pheochromocytoma Benign 1 (2%)
Capsule, Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Adrenal Medulla (53) (54) (53) (53) (53) (53)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 3 (6%) 2 (4%) 2 (4%) 3 (6%) 3 (6%) 3 (6%)
Islets, Pancreatic (51) (54) (53) (53) (52) (52)
Adenoma 1 (2%) 2 (4%)
Carcinoma 1 (2%)
Parathyroid Gland (46) (47) (47) (44) (45) (45)
Adenoma 1 (2%)
Pituitary Gland (53) (54) (52) (53) (53) (52)
Adenoma 4 (8%) 1 (2%)
Meningioma Malignant, Metastatic, Brain 1 (2%)
Pars Distalis, Adenoma 18 (34%) 20 (37%) 26 (50%) 15 (28%) 20 (38%) 10 (19%)
Pars Distalis, Adenoma, Multiple 3 (6%)
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (52) (54) (53) (51) (53) (52)
Bilateral, C-Cell, Adenoma 3 (6%) 3 (6%) 2 (4%) 2 (4%) 1 (2%) 3 (6%)
C-Cell, Adenoma 17 (33%) 12 (22%) 15 (28%) 14 (27%) 12 (23%) 8 (15%)
C-Cell, Carcinoma 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (52) (53) (52) (51) (53)
Ovary (51) (53) (53) (53) (53) (53)
Granulosa Cell Tumor Malignant 1 (2%)
Thecoma Benign 1 (2%)
Periovarian Tissue, Schwannoma Malignant,
Metastatic, Uterus 1 (2%)
Uterus (52) (53) (53) (53) (53) (53)
Adenoma 1 (2%)
Carcinoma 1 (2%) 2 (4%) 1 (2%)
Carcinoma, Multiple 1 (2%)
Hemangiosarcoma 1 (2%)
Leiomyoma 1 (2%)
Polyp Stromal 9 (17%) 7 (13%) 4 (8%) 8 (15%) 9 (17%) 7 (13%)
Polyp Stromal, Multiple 2 (4%) 3 (6%) 1 (2%) 1 (2%)
Squamous Cell Carcinoma 4 (8%)
Squamous Cell Carcinoma, Multiple 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Cervix, Carcinoma 1 (2%)
Cervix, Schwannoma Malignant 1 (2%)
Vagina (1) (1) (3) (3) (1)
Schwannoma Malignant 1 (33%) 1 (100%)
Schwannoma Malignant, Metastatic, Skin 1 (33%)
Squamous Cell Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (54) (53) (53) (53) (53)
Lymph Node (2) (6) (3) (5) (6) (9)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (50%)
Lumbar, Carcinoma, Metastatic, Uterus 1 (17%)
Lymph Node, Mandibular (51) (54) (52) (50) (51) (52)
Lymph Node, Mesenteric (52) (53) (53) (53) (53) (51)
Spleen (51) (54) (53) (53) (52) (52)
Hemangiosarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Thymus (51) (52) (52) (49) (46) (42)
Carcinoma, Metastatic, Lung 1 (2%)
Histiocytic Sarcoma, Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (54) (53) (53) (53) (53)
Adenoma 2 (4%) 1 (2%) 1 (2%)
Carcinoma 3 (6%) 7 (13%) 4 (8%) 2 (4%) 2 (4%)
Carcinoma, Multiple 1 (2%) 1 (2%)
Fibroadenoma 21 (40%) 26 (48%) 17 (32%) 17 (32%) 24 (45%) 20 (38%)
Fibroadenoma, Multiple 12 (23%) 14 (26%) 17 (32%) 12 (23%) 12 (23%) 4 (8%)
Skin (53) (54) (53) (53) (53) (53)
Basal Cell Carcinoma 1 (2%) 1 (2%)
Fibroma 1 (2%) 2 (4%) 1 (2%)
Fibrosarcoma 1 (2%)
Keratoacanthoma 1 (2%)
Lipoma 1 (2%)
Myxosarcoma 1 (2%)
Schwannoma Malignant 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (53) (54) (53) (53) (53) (53)
Cranium, Schwannoma Malignant, Metastatic,
Skin 1 (2%)
Periosteum, Fibrosarcoma 1 (2%)
Skeletal Muscle (1) (2)
Fibrous Histiocytoma 1 (50%)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (54) (53) (53) (53) (53)
Glioma Malignant 1 (2%)
Granular Cell Tumor Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (53) (54) (53) (52) (53) (52)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Page 5
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Cystic Keratinizing Epithelioma 7 (13%)
Cystic Keratinizing Epithelioma, Multiple 2 (4%)
Nephroblastoma, Metastatic, Kidney 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Mediastinum, Sarcoma 1 (2%) 1 (2%)
Nose (53) (54) (53) (53) (53) (53)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2) (2) (1)
Pinna, Neural Crest Tumor 1 (50%)
Harderian Gland (53) (54) (53) (52) (53) (53)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 3 (6%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (54) (53) (53) (53) (53)
Nephroblastoma 2 (4%) 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Stromal Nephroma 1 (2%)
Urinary Bladder (52) (53) (53) (52) (53) (53)
Polyp 1 (2%)
Schwannoma Malignant, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic, Uterus 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(53) *(54) *(53) *(53) *(53) *(53)
Leukemia Granulocytic 1 (2%)
Lymphoma Malignant 1 (2%) 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 NG/KG 3 NG/KG 10 NG/KG 22 NG/KG 46 NG/KG 100
NG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 54 48 44 50 50
Total Primary Neoplasms 116 105 106 89 116 131
Total Animals with Benign Neoplasms 45 49 45 40 46 42
Total Benign Neoplasms 102 86 92 78 88 87
Total Animals with Malignant Neoplasms 13 19 13 11 24 34
Total Malignant Neoplasms 13 19 14 11 28 44
Total Animals with Metastatic Neoplasms 2 3 2 2 3 6
Total Metastatic Neoplasm 6 3 3 3 6 7
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 100 NG/
KG/STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50
Early Deaths
Moribund Sacrifice 16
Natural Death 13
Survivors
Terminal Sacrifice 21
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Intestine Small, Jejunum (50)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
Liver (50)
Cholangiocarcinoma 1 (2%)
Cholangiocarcinoma, Multiple 1 (2%)
Cholangioma 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Adenoma 2 (4%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
Oral Mucosa (11)
Gingival, Squamous Cell Carcinoma 5 (45%)
Pancreas (49)
Acinus, Carcinoma 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (49)
Aorta, Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Heart (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Schwannoma Malignant 3 (6%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 100 NG/
KG/STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50)
Capsule, Schwannoma Malignant, Metastatic,
Heart 1 (2%)
Adrenal Medulla (50)
Pheochromocytoma Complex 1 (2%)
Pheochromocytoma Benign 1 (2%)
Pituitary Gland (50)
Pars Distalis, Adenoma 19 (38%)
Thyroid Gland (49)
Bilateral, C-Cell, Adenoma 2 (4%)
C-Cell, Adenoma 11 (22%)
C-Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49)
Carcinoma, Metastatic, Uterus 1 (2%)
Uterus (50)
Carcinoma 2 (4%)
Polyp Stromal 3 (6%)
Polyp Stromal, Multiple 1 (2%)
Squamous Cell Carcinoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (49)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Spleen (49)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (2%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
Thymus (49)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Page 9
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 100 NG/
KG/STOP
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Adenolipoma 1 (2%)
Carcinoma 1 (2%)
Fibroadenoma 19 (38%)
Fibroadenoma, Multiple 13 (26%)
Skin (50)
Fibroma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Liposarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50)
Squamous Cell Carcinoma, Metastatic, Tongue 1 (2%)
Skeletal Muscle (1)
Fibrous Histiocytoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Schwannoma Malignant, Metastatic, Heart 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 100 NG/
KG/STOP
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50)
Adenolipoma 1 (2%)
Lymphoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 96007-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (TCDD) Date: 09/30/03
Route: GAVAGE Time: 08:37:13
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 100 NG/
KG/STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46
Total Primary Neoplasms 98
Total Animals with Benign Neoplasms 41
Total Benign Neoplasms 74
Total Animals with Malignant Neoplasms 19
Total Malignant Neoplasms 24
Total Animals with Metastatic Neoplasms 5
Total Metastatic Neoplasm 19
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------